key: cord-0826384-08ykjy8g
authors: Preciado, Priscila; Tapia Silva, Leticia M; Ye, Xiaoling; Zhang, Hanjie; Wang, Yuedong; Waguespack, Peter; Kooman, Jeroen P; Kotanko, Peter
title: Arterial oxygen saturation and hypoxemia in hemodialysis patients with COVID-19
date: 2021-02-01
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab019
sha: 9879f4032cc61c39730028a534d888ae2ebe59a5
doc_id: 826384
cord_uid: 08ykjy8g

BACKGROUND: Maintenance hemodialysis (MHD) patients are particularly vulnerable to coronavirus disease 2019 (COVID-19), a viral disease that may cause interstitial pneumonia, impaired alveolar gas exchange and hypoxemia. We ascertained the time course of intradialytic arterial oxygen saturation (SaO(2)) in MHD patients between 4 weeks pre-diagnosis and the week post-diagnosis of COVID-19. METHODS: We conducted a quality improvement project in confirmed COVID-19 in-center MHD patients from 11 dialysis facilities. In patients with an arterio-venous access, SaO(2) was measured 1×/min during dialysis using the Crit-Line monitor (Fresenius Medical Care, Waltham, MA, USA). We extracted demographic, clinical, treatment and laboratory data, and COVID-19-related symptoms from the patients’ electronic health records. RESULTS: Intradialytic SaO(2) was available in 52 patients (29 males; mean ± standard deviation age 66.5 ± 15.7 years) contributing 338 HD treatments. Mean time between onset of symptoms indicative of COVID-19 and diagnosis was 1.1 days (median 0; range 0–9). Prior to COVID-19 diagnosis the rate of HD treatments with hypoxemia, defined as treatment-level average SaO(2) <90%, increased from 2.8% (2–4 weeks pre-diagnosis) to 12.2% (1 week) and 20.7% (3 days pre-diagnosis). Intradialytic O(2) supplementation increased sharply post-diagnosis. Eleven patients died from COVID-19 within 5 weeks. Compared with patients who recovered from COVID-19, demised patients showed a more pronounced decline in SaO(2) prior to COVID-19 diagnosis. CONCLUSIONS: In HD patients, hypoxemia may precede the onset of clinical symptoms and the diagnosis of COVID-19. A steep decline of SaO(2) is associated with poor patient outcomes. Measurements of SaO(2) may aid the pre-symptomatic identification of patients with COVID-19.

The clinical spectrum of coronavirus disease 2019 (COVID- 19) varies from asymptomatic to life-threatening, with respiratory and multiorgan failure [1] [2] [3] [4] [5] [6] . Older age and comorbidities, including chronic kidney disease and dialysis, are risk factors for adverse outcomes [4, 7] .

COVID-19 may cause interstitial pneumonia and impaired gas exchange. Measurement of arterial oxygen saturation (SaO 2 ) provides an easy-to-use, non-invasive means to assess blood oxygenation. Hypoxemia, conventionally defined as an SaO 2 <90%, is a harbinger of clinical instability and progressive hypoxemia is associated with poor outcomes in patients with pulmonary diseases [8] . SaO 2 is used to evaluate the severity of the COVID-19, although it is not widely applied [5, 9] . In the general population, previous studies reported SaO 2 <90% in around 40% of COVID-19 patients at the time of hospital admission [9, 10] . A retrospective study in 36 hospitalized maintenance hemodialysis (MHD) patients with COVID-19 reported a SaO 2 <95% in 61% of the patients; a report of 23 hospitalized MHD patients with COVID-19 indicated a hypoxemia rate of 16% [11, 12] . However, these studies were focused on hospitalized MHD patients; data are limited on non-hospitalized in-center MHD patients.

In MHD patients with arterio-venous vascular access, the Crit-Line monitor (CLM) affords the opportunity to quasicontinuously measure SaO 2 during HD. The goal of our analysis was to interrogate routinely collected intradialytic SaO 2 data to ascertain the frequency and degree of hypoxemia in COVID-19 MHD patients before and after diagnosis.

In this quality improvement project, we focus on MHD patients with confirmed COVID-19 dialyzed in 11 US facilities [seven from the Renal Research Institute (RRI); four from Fresenius Kidney Care (FKC)]. We report observations between 1 February and 30 April 2020. In these clinics, the CLM (Fresenius Medical Care, Waltham, MA, USA) is used as standard of care. Only patients with arterio-venous access and eligible SaO 2 measurements (for definition see below) were included in our analysis. We extracted demographic, clinical, treatment-related and laboratory data, and COVID-19-related signs and symptoms from the patients' electronic health records (EHR). The use of supplemental O 2 during dialysis was documented in the EHR. We defined 'silent' hypoxemia as the presence of SaO 2 <90% without administration of supplemental O 2 . This quality improvement protocol was approved by corresponding committees and legal and compliance officers. Informed consent was waived.

Since 12 March 2020, all in-center MHD patients and clinic staff underwent a systematic screening process prior to admittance to their clinics. They were required to wear gloves and surgical masks while being in the dialysis facility. A trained healthcare worker asked standardized questions regarding recent travel, contact with COVID-19 patients, fever and respiratory symptoms. Body temperature was measured (threshold for a positive test was 37.4 C), and the entrance screening results were documented. Patients who screened negative were admitted to the dialysis facility, where they had again their body temperature measured. Nasopharyngeal or oropharyngeal swabs for reverse transcription polymerase chain reaction (RT-PCR) testing were obtained in patients who presented with any signs and symptoms indicative of COVID-19 or reported a recent exposure to a person with COVID-19. The clinics followed the US Centers for Disease Control and Prevention recommendations for the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (https://www.cdc.gov/coronavirus/2019-ncov/ hcp/dialysis/screening.html).

The CLM is approved by the US Food and Drug Administration for the measurement of hematocrit and O 2 saturation in the extracorporeal circuit. The CLM reports hematocrit and O 2 saturation 1Â/min (an example is shown in Supplementary data, Figure S1 ). Per the manufacturer, the accuracy of SaO 2 measurements is 2%. CLM telemetry readings of SaO 2 were continuously, automatically and securely transferred to either the RRI or FKC data warehouse and were subsequently extracted for joint analysis.

CLM data with the following characteristics were deemed implausible or unreliable and hence excluded: relative blood volume >120% or <60%, SaO 2 >100% or zero, hematocrit levels <15% or >60%, and data points collected before or after dialysis.

Laboratory measurements (Spectra Laboratories, New Jersey, NJ, USA) were downloaded to the RRI and FKC data warehouses and extracted for subsequent joint analysis.

Descriptive statistics comprise mean 6 standard deviation (SD) for continuous variables and percentages for categorical variables. Average treatment-level SaO 2 was calculated utilizing all eligible measurements. The treatment-level average SaO 2 was then used for further analysis. HD treatments were also characterized by mean treatment-level SaO 2 (!90% and <90%). We used SaO 2 available up to 4 weeks pre-diagnosis and the week post-diagnosis for this analysis. Additionally, we also examined HD treatments grouped by mean treatment-level SaO 2 (!90% and <90%) in non-COVID-19 MHD patients.

We report baseline descriptive statistics, group differences [95% confidence intervals (CIs)] in all patients and stratified by survivor status. A baseline period was defined as the time between 4 and 6 weeks before the diagnosis of COVID-19. Next, we report the association between hypoxemia and/or O 2 supplementation with death and hospitalization.

To further assess SaO 2 patterns in relation to outcomes, we used estimates from adaptive spline mixed-effects models [13] . For this analysis, patients were stratified by clinical outcomes into two groups (hospitalization or death; neither of both).

Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and R 3.4.4 (libraries ggplot2, dplyr and mgcv; R Foundation for Statistical Computing, Vienna, Austria).

Between February and April 2020, 1166 MHD patients were dialyzed in these 11 facilities. Eighty patients (6.7% of the total population) were diagnosed with COVID-19. Twenty-five of these 80 COVID-19 patients (31.3%) had no arterio-venous vascular access, making a measurement of SaO 2 by CLM impossible; the baseline characteristics of these 25 patients are shown in Supplementary data, Table S1 . Three COVID-19 patients (3.8%) lacked eligible CLM measurements. The remaining 52 MHD patients contributed in total 338 HD treatments with eligible SaO 2 recordings. Their age was 66.5 6 15.7 years, dialysis vintage was 6.9 6 5.0 years, 44.2% were White, 65.4% males, 81.2% had hypertension, 68.7% diabetes, 31.2% congestive heart failure and 14.6% chronic obstructive pulmonary disease (COPD) ( Table 1) .

Eleven patients expired from COVID-19 within 5 weeks after diagnosis; their baseline characteristics are compared with those of the 41 COVID-19 recovered patients in Table 1 .

Data regarding COVID-19 signs and symptoms were available for 46 of the 52 patients (88.5%). Among those, only one patient was asymptomatic; the remaining patients presented with a variety of symptoms. At presentation, malaise (63%), fever (54%), cough (35%) and shortness of breath (30%) were the most common. Gastrointestinal symptoms were present in five (11%) patients, specifically diarrhea; anosmia or dysgeusia were not reported. Most patients (76.1%) showed first symptoms within 48 h before COVID-19 diagnosis. Naso-pharyngeal swabs for SARS-CoV-2 RT-PCR were collected on average 1.1 days after symptom onset (median 0, range 0-9).

The weekly distribution of HD treatments stratified by SaO 2 levels in the 4 weeks pre-diagnosis is shown in Figure 1 ; the day-by-day distribution in the final pre-diagnosis week is shown in Figure 2 . Because of its effect on SaO 2 , this analysis is limited to SaO 2 recordings from dialysis treatments without the use of supplementary O 2 . Prior to COVID-19 diagnosis, the rate of HD treatments with hypoxemia, i.e. an average SaO 2 <90% during dialysis, increased from 2.9% (2-4 weeks pre-diagnosis) to 12.2% (1 week) and 21.7% (3 days pre-diagnosis). Six days pre-diagnosis, SaO 2 !90% was observed in all HD treatments; 3 days later the rate dropped to 83%. In contrast , 4-6 days pre-diagnosis SaO 2 <90% was not observed, with a significant increase noted 3 days later ( Figure 2 ). In the week following the diagnosis of COVID-19, hypoxemia was present in 5% of the treatments (Figure 1 ).

In 1567 MHD patients without COVID-19 MHD, the rate of HD treatments with hypoxemia remained <5.5% (Supplementary data, Figure S3 ).

In the 4 weeks pre-diagnosis, O 2 supplementation was documented in 5% of HD treatments. In the post-diagnosis week, this rate increased to 19% (Figure 3 ). In the week's pre-and post-diagnosis, we observed seven treatments (10% of all treatments with hypoxemia) with an average intradialytic SaO 2 <90% without a concurrent use of supplemental O 2 , indicative of 'silent' hypoxemia. Indication for O 2 supplementation was based on clinical assessment by the clinic staff and was administered exclusively during the in-center dialysis sessions.

Patients were followed for up to 5 weeks post-diagnosis. During that period, 11 (21.5%) out of the 52 patients died ( Table 1 ). The mean post-diagnosis survival time was 14 days (range 2-24). Twenty-nine patients were hospitalized, with an average length of hospitalization of 14 days (median 14, range 5-20). All patients who died were hospitalized during the course of the disease. Hospitalization was based on clinical assessment and criteria by the emergency room physician. Hypoxemia and/or O 2 supplementation was documented in 4 (36%) of 11 patients who died, compared with 7 (17%) of the 41 patients who survived (Table 2) . Five (18%) out of 28 patients who were hospitalized were either hypoxemic or required O 2 supplementation (Table 3) .

We then stratified patients based on outcome into two groups, i.e. hospitalization and/or death versus non-hospitalized/survival. We analyzed these two groups using adaptive spline mixed-effect models. We analyzed these two groups based on COVID-19 onset of symptoms and on COVID-19 diagnosis. Patients who were hospitalized or passed away showed both a pronounced pre-onset of symptoms and pre-diagnosis SaO 2 decline; this decline was not observed in the non-hospitalized/survival group (Figures 4 and 5) . 

In our analysis, we interrogated routinely collected intradialytic SaO 2 data to ascertain the rate and dynamics of hypoxemia in MHD patients with confirmed COVID-19. This is the first report of SaO 2 levels during dialysis in a larger group of in-center MHD patients with COVID-19. The main finding is a rise in intradialytic hypoxemia rate in the days before onset of symptoms and diagnosis of COVID-19. We also corroborated the presence of 'silent' hypoxemia, defined as SaO 2 <90% without the use of supplemental O 2 .

Hypoxemia results from pathologies that impair pulmonary gas exchange (e.g. pneumonia), respiratory control (e.g. neurological diseases) or ventilation mechanics (e.g. pneumothorax); it may compound tissue hypoxia and organ dysfunction.

Hypoxemia during HD has been well described in the pre-COVID-19 era [14, 15] .

In the general population, hypoxemia, usually defined as SaO 2 <90%, has been described in 9-38% of COVID-19 patients [9, 10, 1] . It is attributed to interstitial pneumonia, reduced alveolar O 2 diffusion, intrapulmonary shunts (V/Q mismatch) and microthrombi [16, 17] . Data on hypoxemia in MHD patients with COVID-19 are scarce. Two reports on MHD patients who had to be hospitalized due to a more severe clinical course of COVID-19 show decreased SaO 2 levels (<95%) and hypoxemia at admission in 16-60% of patients [11, 12] . In our study, patients who were hospitalized and those who expired due to COVID-19 had a higher hypoxemia rate than those who were not hospitalized or expired. Patients who succumbed to COVID-19 infection were older, had more comorbidities and a longer dialysis vintage. These findings corroborated previously reported risk factors for mortality [11, 12, 18] . It is also noticeable that half of our patients with documented hypoxemia or requiring O 2 supplementation during dialysis were hospitalized; almost half of them died from COVID-19.

In our study, malaise and fever were the most common symptoms at presentation, corroborating previous publications [11, 12, [18] [19] [20] ; on the other hand, we found a lower frequency of cough and shortness of breath compared with other cohorts [12, 20, 21] . Patients showed symptoms on average around 1 day before being tested positive for COVID-19. This brief time period indicates that strict screening procedures implemented in dialysis facilities allow for timely identification and isolation of COVID-19-positive patients. Our results show a sharp decline on SaO 2 levels before any symptoms occurred in those patients who required hospitalization or died.

We observed patients who were hypoxemic with an apparent absence of symptoms, a clinical phenotype called 'silent' hypoxemia [22] [23] [24] . The variability in breathing response to hypoxemia, as well as differences in intra-pulmonary shunts early in the course of the disease, have been proposed as explanations of silent hypoxemia [25] . However, its pathophysiology is still poorly understood. Carbon dioxide, the key stimulus of respiratory drive, diffuses roughly 20 times faster than O 2 in liquids. Therefore, in some disease circumstances, O 2 exchange can be compromised before carbon dioxide removal, resulting in hypoxemia without pronounced hypercapnia and hence less shortness of breath. It is also intriguing to speculate that an infection of the central nervous system by SARS-CoV-2 might play a role.

To the best of our knowledge, this is the first report of intradialytic SaO 2 levels in in-center MHD patients before and shortly after COVID-19 diagnosis and symptoms onset. The strength of this report is the routine, quasi-continuous and automatic documentation of SaO 2 during dialysis, allowing us to interrogate a large number of SaO 2 recordings. We acknowledge that our study has some limitations. We lack objective data such as imaging studies that might have been done outside the dialysis units and could provide useful information on the severity of the disease. Unfortunately, such studies are not available due to healthcare regulations. Lastly, there was relatively brief followup after COVID-19 diagnosis. While after May 2020 no new COVID-19 cases were diagnosed in our 11 dialysis, continued vigilance is warranted.

In summary, hypoxemia may precede both the symptoms onset and diagnosis of COVID-19 in MHD patients. Patients with adverse outcomes such as hospitalization or death showed a steeper decline in SaO 2 compared with their fellow patients who had an uncomplicated clinical course. Measurement of SaO 2 may afford nephrologists an opportunity to identify presymptomatic COVID-19 patients and alert them to patients at increased risk of adverse outcomes. Informed by the current data, we posit that routine measurement of SaO 2 in MHD patients is a valuable addition to our surveillance armamentarium.

Supplementary data are available at ckj online. AUTHORS' CONTRIBUTIONS P.P., L.M.T.S., X.Y., H.Z., Y.W. and P.K contributed to the design and implementation of the research. X.Y, H.Z, Y.W. and P.W. analyzed the data. P.P., L.M.T.S and J.P.K wrote the manuscript with input from all authors. P.K directed the project. All authors provided critical feedback and helped shape the research, analysis and manuscript.

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city

Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

British Thoracic Society emergency oxygen audits

Association between hypoxemia and mortality in patients with COVID-19

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States

COVID-19: clinical course and outcomes of 36 maintenance hemodialysis patients from a single center in Spain

SARS-CoV-2 infection in hospitalized patients with kidney disease

Generalized Additive Models: An Introduction with R. 2nd edn

Intradialytic hypoxemia in chronic hemodialysis patients

Intradialytic hypoxemia and clinical outcomes in patients on hemodialysis

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dualenergy CT

Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan

Clinical features of hemodialysis patients with COVID-19: a single-center retrospective study on 32 patients

Presentation and outcomes of patients with ESKD and COVID-19

Outcomes of COVID-19 among patients on in-center hemodialysis: an experience from the epicenter in South Korea

The mystery of the pandemic's 'happy hypoxia

COVID-19 with silent hypoxemia

Why COVID-19 silent hypoxemia is baffling to physicians

Silent" presentation of hypoxemia and cardiorespiratory compensation in COVID-19

The data underlying this article cannot be shared publicly due to company privacy policies. The data will be shared on reasonable request to the corresponding author.